Rapport Therapeutics (RAPP) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.84

Estimate

-$1.22

Surprise

+31.2%

Score today

5.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Rapport Therapeutics (RAPP) reported a narrower loss than forecast — adjusted EPS of -$0.84 against the -$1.22 estimate (a 31.2% beat on a still-unprofitable quarter).

• Rapport Therapeutics Reports Third Quarter 2026 Financial Results and Business Update — fiscal.ai, 2026-11-04
• Rapport Therapeutics Q3 EPS $(0.84) Beats $(1.19) Estimate — benzinga, 2026-11-04
• Rapport Therapeutics Announces Participation in Upcoming Investor Conferences — fiscal.ai, 2026-11-03

TrendMatrix currently rates RAPP Sell at 5.3/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +31.2% surprise compares with a +11.2% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$25.93

Price target

$59.41

Stop

$24.11

Upside to target

+129.1%

Reward-to-risk

8.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.50B

P/E (fwd)

-5.1

52-week range

$22.06–$52.93

Off 52-week high

51.0%

RSI (14)

42

Volume vs avg

0.64×

Score today

5.3/10